Advertisement
Advertisement
MLYS
Mineralys Therapeutics, Inc. Common Stock
15.33
USDSponsored
+0.09
+0.59%
Nov 06, 15:59 UTC -5
Closed
After-Market
15.34
+0.01
+0.07%
Mineralys Therapeutics, Inc. Common Stock (MLYS) Earnings
MLYS Earnings Reports
Positive Surprise Ratio
MLYS beat 11 of 16 last estimates.
69%
Next Report
Date of Next Report
Mar 10, 2027
Estimate for Q4 26 (Revenue/ EPS)
--
/-$0.60
Implied change from Q3 26 (Revenue/ EPS)
--
/-6.25%
Implied change from Q4 25 (Revenue/ EPS)
--
/+50.00%
Mineralys Therapeutics, Inc. Common Stock earnings per share and revenue
On Nov 04, 2026, MLYS reported earnings of -0.64 USD per share (EPS) for Q3 26, missing the estimate of -0.54 USD, resulting in a -16.87% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -10.35% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.60 USD, with revenue projected to reach -- USD, implying an decrease of -6.25% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
$0.28
Surprise
+373.86%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
FAQ
What were Mineralys Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Mineralys Therapeutics, Inc. Common Stock reported EPS of -$0.64, missing estimates by -16.87%, and revenue of $0.00, 0% as expectations.
How did the market react to Mineralys Therapeutics, Inc. Common Stock's Q3 2026 earnings?
The stock price moved down -10.35%, changed from $17.00 before the earnings release to $15.24 the day after.
When is Mineralys Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 10, 2027.
What are the forecasts for Mineralys Therapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, Mineralys Therapeutics, Inc. Common Stock is expected to report EPS of -$0.60 and revenue of -- for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.